DMH-1 (Synonyms: BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482) |
Catalog No.GC14298
One-Click Copy Product Info
|
DMH-1 is a selective bone morphogenetic protein (BMP) type I receptor ALK2 inhibitor with an IC50 value of 108nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1206711-16-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DMH-1 is a selective bone morphogenetic protein (BMP) type I receptor ALK2 inhibitor with an IC50 value of 108nM. DMH-1 blocks BMP receptor activation, thereby inhibiting Smad1/5/8 phosphorylation and downregulating Id1, Id2, and Id3 expression. DMH-1 suppresses BMP-mediated osteogenesis, mineralization, and cancer cell proliferation while promoting cardiomyocyte differentiation. DMH-1 can be used in studies related to tumors, stem cell and developmental biology, musculoskeletal and genetic diseases[1-4].
In vitro, treatment of A549 and H460 cells with 1-5μM DMH-1 for 24-72 hours decreased p-Smad1/5/8 levels and downregulated Id1, Id2, and Id3 mRNA expression. DMH-1 slowed cell migration, reduced cell proliferation, and increased the proportion of dead cells[5]. Treatment of A549 and H1299 cells with 1μM DMH-1 for 7-14 days reduced viable cell numbers, inhibited colony formation, and decreased soft agar anchorage-independent growth colonies[6]. Pretreatment of Hep3B cells with 10nM DMH-1 for 15-20 minutes followed by stimulation with 200ng/mL recombinant human BMP13 for 15 minutes to 24 hours blocked BMP13-induced SMAD1/5/9 phosphorylation, reduced ID1 mRNA expression, and inhibited cell proliferation[7].
In vivo, intraperitoneal injection of 5mg/kg DMH-1 every other day for 16 consecutive days to NSG mice bearing PC3-TxR cells reduced tumor volume and tumor weight and decreased Ki67-positive cell proportion in tumor tissue[8]. After intramuscular injection of Adex-cre and 1.5μg cardiotoxin into the hindlimb of caALK2fl/fl mice, intraperitoneal injection of 10mg/kg DMH-1 for 28 days. DMH-1 reduced the radiographic area of hindlimb heterotopic ossification[9]. Starting 3 days before left anterior descending coronary artery ligation surgery, intraperitoneal injection of 5mg/kg DMH-1 every other day to C57BL/6 mice until 28 days after surgery. DMH-1 decreased left ventricular ejection fraction and left ventricular fractional shortening, increased left ventricular end-diastolic diameter and left ventricular end-systolic diameter, and aggravated myocardial fibrosis area[10].
References:
[1] Hochgerner M, Jiang Y, Sun S, et al. Loss of ALK3 Ameliorates Acute but Aggravates Chronic Lung Inflammation In Vivo. Immunology. 2025 Oct;176(2):224-236.
[2] Zhang X, Miao Y, Li Z, et al. ACVR1 drives neuropathic pain by regulating NLRP3-Induced neuronal pyroptosis through the p38 and Smad1/5/8 pathways. Neuropharmacology. 2025 Aug 15;274:110469.
[3] Luo J, Wang Y, Chang HM, et al. ID3 mediates BMP2-induced downregulation of ICAM1 expression in human endometiral stromal cells and decidual cells. Front Cell Dev Biol. 2023 Feb 24;11:1090593.
[4] Zhang Y, Zhu H, Chang HM, et al. ALK3-SMAD1/5 Signaling Mediates the BMP2-Induced Decrease in PGE2 Production in Human Endometrial Stromal Cells and Decidual Stromal Cells. Front Cell Dev Biol. 2020 Sep 15;8:573028.
[5] Hao J, Lee R, Chang A, et al. DMH1, a Small Molecule Inhibitor of BMP Type I Receptors, Suppresses Growth and Invasion of Lung Cancer. PLoS ONE. 2014 Mar 6;9(3):e90748.
[6] Langenfeld E, Hong CC, Lanke G, et al. Bone Morphogenetic Protein Type I Receptor Antagonists Decrease Growth and Induce Cell Death of Lung Cancer Cell Lines. PLoS ONE. 2013 Apr 12;8(4):e61256.
[7] Kersten V, Seitz T, Sommer J, et al. Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro. Int J Mol Sci. 2023 Jul 4;24(13):11059.
[8] Xie C, Wang Z, Ba Y, et al. BMP signaling inhibition overcomes chemoresistance of prostate cancer. Am J Cancer Res. 2023;13(9):4073-4086.
[9] Pan H, Fleming N, Hong CC, et al. Methods for the reliable induction of heterotopic ossification in the conditional Alk2Q207D mouse. J Musculoskelet Neuronal Interact. 2020;20(1):149-159.
[10] Liu M, Pei J, Zeng C, et al. BMP7 attenuates myocardial injury and preserves cardiac function after myocardial infarction by inhibiting cardiomyocyte pyroptosis. Apoptosis. 2026;31:57.
| Cell experiment [1]: | |
|
Cell lines |
Hep3B, HepG2, PLC/PRF/5 cells (human hepatocellular carcinoma cell line) |
|
Preparation Method |
Hep3B, HepG2 and PLC/PRF/5 cells were maintained in appropriate medium. Hep3B cells were preincubated with 10nM DMH-1 for 15min before 15min stimulation with 200ng/mL recombinant human BMP13. Hep3B cells were pretreated with 10nM DMH-1 for 20min before 8h stimulation with 200ng/mL recombinant human BMP13 for mRNA analysis. Hep3B cells were treated with 10nM DMH-1 for 15min before 24h stimulation with 200ng/mL recombinant human BMP13 for proliferation assay. |
|
Reaction Conditions |
10nM; 15min-24h |
|
Applications |
DMH-1 completely blocked BMP13-induced SMAD1/5/9 phosphorylation in Hep3B cells. DMH-1 reduced BMP13-induced ID1 mRNA expression in Hep3B cells. DMH-1 completely inhibited BMP13-induced proliferation of Hep3B cells. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6 mice |
|
Preparation Method |
Mice were intraperitoneally injected with 5mg/kg DMH-1 every other day starting 3 days before left anterior descending coronary artery (LAD) ligation and continuing to 28 days after surgery. Cardiac function, infarct size, and fibrosis were assessed by echocardiography, TTC staining, and Masson staining at 28 days after myocardial infarction (MI). |
|
Dosage form |
5mg/kg; i.p.; every other day from 3 days before LAD ligation to 28 days after surgery |
|
Applications |
DMH-1 reduced left ventricular ejection fraction and left ventricular fractional shortening. DMH-1 increased left ventricular end-diastolic diameter and left ventricular end-systolic diameter. DMH-1 increased myocardial fibrosis area in the aortic and ventricular sections. |
References: [1] Kersten V, Seitz T, Sommer J, et al. Bone Morphogenetic Protein 13 Has Protumorigenic Effects on Hepatocellular Carcinoma Cells In Vitro. Int J Mol Sci. 2023 Jul 4;24(13):11059. [2] Liu M, Pei J, Zeng C, et al. BMP7 attenuates myocardial injury and preserves cardiac function after myocardial infarction by inhibiting cardiomyocyte pyroptosis. Apoptosis. 2026;31:57. | |
| Cas No. | 1206711-16-1 | SDF | |
| Synonyms | BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482 | ||
| Canonical SMILES | CC(C)OC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=CC=NC5=CC=CC=C45)N=C2 | ||
| Formula | C24H20N4O | M.Wt | 380.44 |
| Solubility | ≥ 9.511mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6285 mL | 13.1427 mL | 26.2854 mL |
| 5 mM | 525.7 μL | 2.6285 mL | 5.2571 mL |
| 10 mM | 262.9 μL | 1.3143 mL | 2.6285 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)